A New Blueprint for Safer Thiopurine Therapy
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has released its 2025 update to the guideline for dosing thiopurine drugs—including azathioprine, mercaptopurine, and thioguanine—based on genetic testing. The guideline details how specific genetic variants in the TPMT and NUDT15 enzymes, which are critical for metabolizing these drugs, can predict a patient’s risk of severe adverse effects like myelosuppression. It provides actionable recommendations for adjusting starting doses according to an individual’s genotype, a practice essential for personalized medicine and therapeutic drug monitoring (TDM).
Why it might matter to you: This guideline directly impacts clinical chemistry and molecular diagnostics labs, as it mandates precise genotyping assays to guide pharmacotherapy. For professionals focused on analytical accuracy and quality control, implementing these updated protocols is crucial for preventing pre-analytical and post-analytical errors in TDM. It represents a significant step in lab workflow optimization, ensuring that diagnostic algorithms for drug dosing are both evidence-based and tailored to diverse patient populations.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
